| Primary |
| Breast Cancer |
18.7% |
| Product Used For Unknown Indication |
11.8% |
| Diffuse Large B-cell Lymphoma |
9.1% |
| Non-hodgkin's Lymphoma |
7.2% |
| Chronic Lymphocytic Leukaemia |
5.5% |
| Hodgkin's Disease |
5.4% |
| Prophylaxis |
5.3% |
| Multiple Myeloma |
5.1% |
| B-cell Lymphoma |
4.7% |
| Burkitt's Lymphoma |
4.3% |
| Acute Lymphocytic Leukaemia |
4.1% |
| Drug Use For Unknown Indication |
3.6% |
| Bone Marrow Conditioning Regimen |
3.1% |
| Lymphoma |
2.2% |
| Wegener's Granulomatosis |
2.0% |
| Chemotherapy |
1.9% |
| Drug Exposure During Pregnancy |
1.7% |
| Prophylaxis Against Graft Versus Host Disease |
1.5% |
| Premedication |
1.4% |
| Acute Myeloid Leukaemia |
1.3% |
|
| White Blood Cell Count Decreased |
9.2% |
| Drug Exposure During Pregnancy |
8.7% |
| Vomiting |
8.0% |
| Pyrexia |
7.5% |
| Sepsis |
6.6% |
| Myelodysplastic Syndrome |
6.3% |
| Neutropenia |
6.0% |
| Febrile Neutropenia |
5.8% |
| Death |
5.3% |
| Toxicity To Various Agents |
4.8% |
| Thrombocytopenia |
4.7% |
| Pneumonia |
4.2% |
| Maternal Exposure During Pregnancy |
3.9% |
| Neutropenic Sepsis |
3.8% |
| Venoocclusive Liver Disease |
2.7% |
| Metastasis |
2.6% |
| Septic Shock |
2.6% |
| Pneumocystis Jiroveci Pneumonia |
2.5% |
| Infection |
2.4% |
| Progressive Multifocal Leukoencephalopathy |
2.4% |
|
| Secondary |
| Diffuse Large B-cell Lymphoma |
21.2% |
| Breast Cancer |
11.1% |
| Drug Use For Unknown Indication |
9.3% |
| Product Used For Unknown Indication |
7.2% |
| Acute Lymphocytic Leukaemia |
7.1% |
| Non-hodgkin's Lymphoma |
6.5% |
| B-cell Lymphoma |
6.4% |
| Chronic Lymphocytic Leukaemia |
4.7% |
| Multiple Myeloma |
4.2% |
| Mantle Cell Lymphoma |
3.4% |
| Prophylaxis |
3.2% |
| Hodgkin's Disease |
3.0% |
| Burkitt's Lymphoma |
2.8% |
| Lymphoma |
2.5% |
| T-cell Lymphoma |
1.7% |
| Peripheral T-cell Lymphoma Unspecified |
1.6% |
| Chemotherapy |
1.1% |
| Plasma Cell Myeloma |
1.1% |
| Stem Cell Transplant |
1.0% |
| Prophylaxis Against Graft Versus Host Disease |
1.0% |
|
| Febrile Neutropenia |
14.0% |
| Neutropenia |
7.8% |
| Thrombocytopenia |
7.2% |
| Pyrexia |
6.9% |
| Vomiting |
6.4% |
| Sepsis |
6.4% |
| White Blood Cell Count Decreased |
6.0% |
| Death |
5.5% |
| Pneumonia |
5.0% |
| Myelodysplastic Syndrome |
4.4% |
| Infection |
3.5% |
| Acute Myeloid Leukaemia |
3.4% |
| Pneumocystis Jiroveci Pneumonia |
3.3% |
| Septic Shock |
3.2% |
| Progressive Multifocal Leukoencephalopathy |
3.2% |
| Pulmonary Embolism |
3.1% |
| Respiratory Failure |
3.0% |
| Pancytopenia |
2.9% |
| Weight Decreased |
2.6% |
| Stomatitis |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
11.9% |
| Drug Use For Unknown Indication |
11.3% |
| Breast Cancer |
10.4% |
| Diffuse Large B-cell Lymphoma |
6.5% |
| Prophylaxis Against Graft Versus Host Disease |
6.2% |
| Non-hodgkin's Lymphoma |
6.2% |
| Prophylaxis |
5.6% |
| Chemotherapy |
5.1% |
| B-cell Lymphoma |
4.8% |
| Bone Marrow Conditioning Regimen |
4.8% |
| Multiple Myeloma |
4.6% |
| Stem Cell Transplant |
4.0% |
| Lymphoma |
3.9% |
| Acute Lymphocytic Leukaemia |
3.8% |
| Chronic Lymphocytic Leukaemia |
2.7% |
| Infection Prophylaxis |
2.3% |
| Premedication |
2.0% |
| Cord Blood Transplant Therapy |
1.4% |
| Bone Marrow Transplant |
1.3% |
| Mantle Cell Lymphoma |
1.3% |
|
| Febrile Neutropenia |
8.9% |
| Vomiting |
8.8% |
| Pyrexia |
7.5% |
| Thrombocytopenia |
7.0% |
| Neutropenia |
6.9% |
| Sepsis |
6.6% |
| Death |
6.1% |
| White Blood Cell Count Decreased |
5.9% |
| Progressive Multifocal Leukoencephalopathy |
5.8% |
| Drug Ineffective |
5.2% |
| Respiratory Failure |
3.9% |
| Weight Decreased |
3.7% |
| Thrombotic Microangiopathy |
3.3% |
| Pneumocystis Jiroveci Pneumonia |
3.1% |
| Pneumonia |
3.1% |
| Renal Failure |
3.0% |
| Pulmonary Embolism |
2.9% |
| Disease Progression |
2.9% |
| Septic Shock |
2.7% |
| Pancytopenia |
2.6% |
|
| Interacting |
| Breast Cancer |
25.5% |
| Product Used For Unknown Indication |
20.6% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
9.8% |
| Non-hodgkin's Lymphoma |
7.9% |
| Drug Use For Unknown Indication |
6.5% |
| Metastasis |
5.7% |
| Lymphoma |
5.4% |
| Chronic Lymphocytic Leukaemia |
3.8% |
| Diffuse Large B-cell Lymphoma |
3.3% |
| Hodgkin's Disease |
2.2% |
| Breast Cancer Metastatic |
1.1% |
| Epilepsy |
1.1% |
| Heart Transplant |
1.1% |
| Medulloblastoma |
1.1% |
| Nausea |
1.1% |
| Pneumonia Bacterial |
1.1% |
| Anesthesia |
0.8% |
| Depression |
0.8% |
| Sarcoma |
0.8% |
| Bronchopulmonary Aspergillosis |
0.5% |
|
| Drug Interaction |
21.8% |
| Osteonecrosis |
12.7% |
| Weight Decreased |
9.1% |
| Nausea |
7.3% |
| Agranulocytosis |
5.5% |
| Hepatitis Fulminant |
5.5% |
| Pneumonitis |
5.5% |
| Extrasystoles |
3.6% |
| Leukopenia |
3.6% |
| Neutropenia |
3.6% |
| Pyrexia |
3.6% |
| Vascular Graft Complication |
3.6% |
| Bone Marrow Failure |
1.8% |
| Dizziness |
1.8% |
| Fat Embolism |
1.8% |
| Musculoskeletal Pain |
1.8% |
| Neoplasm Progression |
1.8% |
| Personality Change |
1.8% |
| Pneumonitis Chemical |
1.8% |
| Sepsis |
1.8% |
|
